You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 14, 2025

Almirall Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Almirall
International Patents:219
US Patents:18
Tradenames:11
Ingredients:10
NDAs:12

Drugs and US Patents for Almirall

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Almirall ALTABAX retapamulin OINTMENT;TOPICAL 022055-001 Apr 12, 2007 DISCN Yes No 8,207,191 ⤷  Try for Free ⤷  Try for Free
Almirall SEYSARA sarecycline hydrochloride TABLET;ORAL 209521-002 Oct 1, 2018 RX Yes No 8,318,706 ⤷  Try for Free Y Y ⤷  Try for Free
Almirall KLISYRI tirbanibulin OINTMENT;TOPICAL 213189-001 Dec 14, 2020 RX Yes Yes 10,669,236 ⤷  Try for Free Y Y ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Almirall

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Almirall XOLEGEL ketoconazole GEL;TOPICAL 021946-001 Jul 28, 2006 7,179,475 ⤷  Try for Free
Almirall VELTIN clindamycin phosphate; tretinoin GEL;TOPICAL 050803-001 Jul 16, 2010 5,690,923 ⤷  Try for Free
Almirall ALTABAX retapamulin OINTMENT;TOPICAL 022055-001 Apr 12, 2007 RE39128 ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for ALMIRALL drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Gel 7.5% ➤ Subscribe 2017-02-13

Supplementary Protection Certificates for Almirall Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1304992 122013000081 Germany ⤷  Try for Free PRODUCT NAME: CLINDAMYCIN (ALS CLINDAMYCIN-PHOSPHAT) UND TRETINOIN; NAT. REGISTRATION NO/DATE: 85210.00.00 20130611; FIRST REGISTRATION: IRLAND PA1332/043/001 20130322
1836169 SPC/GB22/002 United Kingdom ⤷  Try for Free PRODUCT NAME: TIRBANIBULIN; REGISTERED: UK EU/1/21/1558(FOR NI) 20210719; UK FURTHER MA ON IPSUM 20210719
1836169 122021000066 Germany ⤷  Try for Free PRODUCT NAME: KLISYRI TIRBANIBULIN; REGISTRATION NO/DATE: EU/1/21/1558 20210716
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Almirall Market Analysis and Financial Projection

Pharmaceutical Competitive Landscape Analysis: Almirall – Market Position, Strengths & Strategic Insights

In the dynamic world of pharmaceuticals, Almirall stands out as a Spanish company with a rich history and a laser focus on medical dermatology. Founded in 1944, Almirall has evolved into a global player, making significant strides in the pharmaceutical industry. Let's dive deep into Almirall's market position, strengths, and strategic insights to understand how this company has carved its niche in the competitive pharmaceutical landscape.

Almirall's Market Position

Almirall has established itself as a leading player in the pharmaceutical industry, particularly in the field of medical dermatology. The company's strategic focus on this niche has allowed it to build a strong market position and differentiate itself from competitors.

European Leadership in Medical Dermatology

Almirall has solidified its position as the leading European company in medical dermatology[1]. This achievement is a testament to the company's dedication to innovation and its ability to meet the needs of patients and healthcare professionals in this specialized field.

Global Presence

While Almirall's roots are in Spain, the company has expanded its reach far beyond its home country. With a direct presence in 20 countries through 15 subsidiaries in Europe and the USA, Almirall has truly become a global player[1]. This international footprint allows the company to tap into diverse markets and leverage opportunities for growth across different regions.

Financial Performance

Almirall's market position is further strengthened by its solid financial performance. In 2023, the company generated total revenues of €898.8 million[1]. This financial success provides Almirall with the resources to invest in research and development, expand its product portfolio, and pursue strategic initiatives to enhance its market position.

Almirall's Key Strengths

Almirall's success in the pharmaceutical industry can be attributed to several key strengths that set it apart from competitors.

Focus on Medical Dermatology

One of Almirall's primary strengths is its dedicated focus on medical dermatology. By concentrating its efforts on this specific therapeutic area, Almirall has been able to develop deep expertise and build a strong reputation among dermatologists and patients alike. This specialization allows the company to stay at the forefront of advancements in dermatological treatments and meet unmet medical needs in this field.

Strong R&D Capabilities

Almirall's commitment to research and development is a cornerstone of its success. The company invests significantly in R&D, with 12% of net sales dedicated to this crucial area in 2023[1]. This investment in innovation enables Almirall to develop new and improved treatments, staying ahead of the curve in the rapidly evolving pharmaceutical landscape.

Diverse Product Portfolio

Almirall boasts a diverse portfolio of products across various dermatological conditions. From treatments for psoriasis and atopic dermatitis to solutions for acne and actinic keratosis, Almirall offers a comprehensive range of options for patients and healthcare providers[1]. This diverse portfolio not only caters to different patient needs but also helps mitigate risks associated with reliance on a single product or therapeutic area.

Commercial Excellence

Almirall's success is not just about developing innovative products; it's also about effectively bringing these products to market. The company has demonstrated strong commercial capabilities, particularly in launching and growing its biologics portfolio. The successful launches of products like Ilumetri® and Ebglyss® across key European markets showcase Almirall's commercial prowess[2].

Strategic Insights: Almirall's Path to Growth

Almirall's strategy for growth and market leadership is multifaceted, focusing on several key areas that leverage its strengths and address market opportunities.

Biologics as Growth Drivers

Almirall is placing a significant emphasis on its biologics portfolio as a key driver of future growth. The company's psoriasis and atopic dermatitis franchises, led by Ebglyss® and Ilumetri®, are anticipated to generate over 800 million euros in annual peak sales[2]. This focus on high-potential biologics positions Almirall for substantial growth in the coming years.

"Growth of Almirall's psoriasis and atopic dermatitis franchises is anticipated to lead to over 800 million in annual peak sales in biologics, driven by Ebglyss® and Ilumetri®"[2]

Sustained Double-Digit Growth

Almirall is not just focused on short-term gains; the company has set its sights on sustained long-term growth. The company forecasts sustained double-digit growth of net sales (CAGR 2023-2030) and a substantial margin expansion[2]. This ambitious growth trajectory is underpinned by Almirall's focus on medical dermatology, commercial excellence, and continued investment in R&D.

Investment in Commercial Excellence and R&D

To realize its market potential and maintain its leadership position in European medical dermatology, Almirall is making strategic investments in commercial excellence, R&D, and science leadership[2]. These investments are crucial for driving innovation, bringing new products to market, and effectively commercializing its portfolio.

Global Expansion

While Almirall has a strong presence in Europe, the company is also looking towards global expansion as a key strategic initiative. With operations in multiple countries and partnership agreements in over 100 countries[5], Almirall is well-positioned to tap into new markets and expand its global footprint.

Competitive Landscape: Almirall's Position Among Rivals

In the competitive pharmaceutical landscape, Almirall has carved out a unique position for itself, particularly in the field of medical dermatology. Let's examine how Almirall stacks up against its competitors.

Specialization as a Differentiator

While many large pharmaceutical companies have diverse portfolios spanning multiple therapeutic areas, Almirall's focus on medical dermatology sets it apart. This specialization allows Almirall to compete effectively against larger, more diversified competitors by offering deep expertise and a comprehensive range of dermatological treatments.

Innovation in a Niche Market

Almirall's commitment to innovation in dermatology gives it a competitive edge in this niche market. By focusing its R&D efforts on unmet needs in dermatology, Almirall can develop targeted solutions that may be overlooked by broader-focused competitors.

European Leadership

As the leading European company in medical dermatology[1], Almirall has a strong competitive position in its home market. This leadership status provides Almirall with significant brand recognition and trust among European dermatologists and patients.

Challenges and Opportunities in the Pharmaceutical Landscape

While Almirall has established a strong position in the pharmaceutical industry, it faces both challenges and opportunities in the evolving landscape.

Challenges

  1. Increasing Competition:

    The pharmaceutical industry is highly competitive, with both established players and new entrants vying for market share. Almirall must continue to innovate and differentiate its offerings to maintain its competitive edge.
  2. Regulatory Environment:

    The pharmaceutical industry is heavily regulated, and changes in regulations can impact product development, approval processes, and market access. Almirall must navigate this complex regulatory landscape effectively.
  3. Pricing Pressures:

    Healthcare systems worldwide are under pressure to control costs, which can lead to pricing pressures on pharmaceutical products. Almirall needs to demonstrate the value of its treatments to justify pricing and secure market access.

Opportunities

  1. Growing Dermatology Market:

    The global dermatology market is expected to grow significantly in the coming years, driven by factors such as an aging population and increasing prevalence of skin disorders. This growth presents substantial opportunities for Almirall to expand its market share.
  2. Emerging Markets:

    Expanding into emerging markets offers Almirall the opportunity to tap into new patient populations and drive growth beyond its core European markets.
  3. Digital Health:

    The integration of digital technologies in healthcare presents opportunities for Almirall to enhance patient care, improve treatment outcomes, and differentiate its offerings.

Future Outlook: Almirall's Path Forward

Looking ahead, Almirall is well-positioned to capitalize on its strengths and market opportunities. The company's focus on medical dermatology, combined with its strong R&D capabilities and commercial excellence, provides a solid foundation for future growth.

Continued Focus on Innovation

Almirall's commitment to innovation will likely remain a key driver of its future success. By continuing to invest in R&D and focusing on unmet needs in dermatology, Almirall can maintain its competitive edge and bring new, innovative treatments to market.

Expansion of Biologics Portfolio

The anticipated growth of Almirall's biologics portfolio, particularly Ebglyss® and Ilumetri®, is expected to be a significant driver of the company's future performance. Successfully scaling these products and potentially expanding their indications could substantially boost Almirall's market position and financial results.

Global Growth

While Almirall has a strong presence in Europe, there is significant potential for global expansion. By leveraging its expertise in medical dermatology and its successful product portfolio, Almirall can tap into new markets and drive growth on a global scale.

Key Takeaways

  1. Almirall has established itself as the leading European company in medical dermatology, with a strong global presence and solid financial performance.

  2. The company's key strengths include its focus on medical dermatology, strong R&D capabilities, diverse product portfolio, and commercial excellence.

  3. Almirall's growth strategy centers on its biologics portfolio, with products like Ebglyss® and Ilumetri® expected to drive significant future growth.

  4. The company faces challenges such as increasing competition and regulatory pressures, but also has opportunities in the growing dermatology market and emerging markets.

  5. Almirall's future outlook is positive, with continued focus on innovation, expansion of its biologics portfolio, and global growth as key drivers of future success.

FAQs

  1. What is Almirall's primary focus in the pharmaceutical industry?

    Almirall primarily focuses on medical dermatology, developing and commercializing treatments for various skin conditions.

  2. How does Almirall's R&D investment compare to its net sales?

    In 2023, Almirall invested 12% of its net sales in research and development.

  3. What are Almirall's key growth drivers for the future?

    Almirall's key growth drivers include its biologics portfolio, particularly Ebglyss® and Ilumetri®, which are expected to generate over 800 million euros in annual peak sales.

  4. How many countries does Almirall have a direct presence in?

    Almirall has a direct presence in 20 countries through 15 subsidiaries in Europe and the USA.

  5. What is Almirall's projected growth rate for net sales?

    Almirall forecasts sustained double-digit growth of net sales (CAGR) from 2023 to 2030.

Sources cited:

  1. https://en.wikipedia.org/wiki/Almirall
  2. https://www.biospace.com/press-releases/almirall-at-the-jpmorgan-conference-entering-a-new-era-of-sustained-growth
  3. https://www.almirall.com/our-purpose

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.